Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 334 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CSF collection Clear all
Recruiting Phase 1Phase 2 Interventional

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

NCT07437963
View directory record Official record
Conditions
Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma, Refractory Neuroblastoma
Interventions
Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Dinutuximab, Echocardiography Test, FDG-Positron Emission Tomography, Iberdomide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nuclear Radiology Imaging Procedure, Sargramostim, Topotecan
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
2
States / cities
Oakland, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 26, 2026, 9:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

NCT07468136
View directory record Official record
Conditions
Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma, Glioblastoma, IDH-Wildtype, Malignant Glioma
Interventions
Biospecimen Collection, Eflornithine, Lumbar Puncture, Magnetic Resonance Imaging, Retifanlimab, Tumor Resection
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 26, 2026, 9:32 AM EDT
Recruiting Phase 2 Interventional

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

NCT07288034
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Chemotherapy, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Monitoring, Positron Emission Tomography, Surveillance, Tremelimumab
Drug · Biological · Procedure + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
13
States / cities
Goodyear, Arizona • Corona, California • Duarte, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 26, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Collection of Transplant Stem Cells for Plasma Cell Myeloma

NCT01547806
View directory record Official record
Conditions
Plasma Cell Myeloma, Multiple Myeloma
Interventions
Filgrastim, Plerixafor, Apheresis
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 26, 2026, 9:32 AM EDT
Completed Early Phase 1 Interventional

Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)

NCT03591757
View directory record Official record
Conditions
Transthyretin Amyloidosis, Amyloidosis, Leptomeningeal, Transthyretin-Related
Interventions
Tolcapone
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 26, 2026, 9:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

NCT03068819
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
CIML NK Cell Infusion, CD3+ T Cell Product Infusion, Leukapheresis
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 26, 2026, 9:32 AM EDT
Completed Early Phase 1 Interventional

GCSF Adjunct Therapy for Biliary Atresia

NCT03395028
View directory record Official record
Conditions
Biliary Atresia
Interventions
Granulocyte Colony-Stimulating Factor
Drug
Lead sponsor
Holterman, Ai-Xuan, M.D.
Individual
Eligibility
2 Weeks to 180 Days
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 26, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

NCT00043979
View directory record Official record
Conditions
Sarcoma
Interventions
F-18 Fluorodeoxyglucose, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, doxorubicin hydrochloride, etoposide, fludarabine phosphate, melphalan, prednisone, sirolimus, tacrolimus, vincristine sulfate, peripheral blood stem cell transplantation, Filgrastim, Peripheral Blood Stem Cell donation
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 26, 2026, 9:32 AM EDT
Completed Not applicable Interventional Results available

Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major

NCT00658385
View directory record Official record
Conditions
Beta Thalassemia Major, Congenital Anemias
Interventions
GCSF, Central venous line placement, Stem cell Collection (leukapheresis)
Genetic
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 26, 2026, 9:32 AM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Women With Stage IV Breast Cancer

NCT00027807
View directory record Official record
Conditions
Breast Cancer
Interventions
Aldesleukin, Sargramostim, therapeutic autologous lymphocytes
Biological
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 26, 2026, 9:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

NCT03952637
View directory record Official record
Conditions
Lysosomal Diseases, Gangliosidosis, GM1
Interventions
AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam
Biological · Procedure · Drug + 3 more
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
6 Months to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 26, 2026, 9:32 AM EDT
Completed Phase 1 Interventional

Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma

NCT00458653
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dendritic Cell Tumor Fusion
Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2020
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 26, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dynamic Measures of Neurochemistry in Mood Disorders

NCT00178828
View directory record Official record
Conditions
Depression
Interventions
sertraline, bupropion
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 26, 2026, 9:32 AM EDT
Recruiting Not applicable Interventional

Examining the Feasibility of Using Pressure Gradient Regulated Automated Cerebral Spinal Fluid Drainage During External Lumbar Drain Trials

NCT07494812
View directory record Official record
Conditions
NPH (Normal Pressure Hydrocephalus)
Interventions
Intellidrop Automated CSF Drainage System
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
60 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 26, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors

NCT00997529
View directory record Official record
Conditions
Metastatic Solid Tumor
Interventions
nonmyeloablative stem cell transplant
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 26, 2026, 9:32 AM EDT
Completed Not applicable Interventional Results available

Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies

NCT00741455
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Stem Cell Transplant, G-CSF, Fludarabine, cyclophosphamide, Cyclosporine, Methotrexate
Procedure · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 26, 2026, 9:32 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

NCT01318317
View directory record Official record
Conditions
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Filgrastim, Genetically Engineered Lymphocyte Therapy, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Plerixafor, Rituximab
Procedure · Biological · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 26, 2026, 9:32 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

APOE in the Predisposition to, Protection From, and Prevention of Alzheimer's Disease

NCT04994847
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Amyloid and Tau PET
Drug
Lead sponsor
Banner Health
Other
Eligibility
50 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 26, 2026, 9:32 AM EDT
Recruiting Not applicable Interventional

Investigation of the Delve Detect Cerebrospinal Fluid (CSF) Metagenomic Next-generation Sequencing (mNGS) Test When Used for the Initial Diagnostic Workup of Patients With Suspected Central Nervous System (CNS) Infection

NCT07435649
View directory record Official record
Conditions
Central Nervous System Infection
Interventions
Delve Detect CSF mNGS Test, Real-World Data
Diagnostic Test · Other
Lead sponsor
Delve Bio, Inc.
Industry
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 26, 2026, 9:32 AM EDT
Recruiting Phase 3 Interventional

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

NCT06500481
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Involved-Field Radiation Therapy, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Craniospinal Irradiation, Quality-of-Life Assessment
Procedure · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
58
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Encinitas, California + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 26, 2026, 9:32 AM EDT
Recruiting Phase 2 Interventional

Combination Therapy for the Treatment of Diffuse Midline Gliomas

NCT05009992
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma, WHO Grade III Glioma
Interventions
ONC201, Radiation Therapy, Paxalisib, DNX-2401
Drug · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years to 39 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 26, 2026, 9:32 AM EDT
Completed Phase 1 Interventional

Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant

NCT01026987
View directory record Official record
Conditions
Stem Cell Transplant Patients
Interventions
G-CSF, AMD3100, Leukapheresis, Stem Cell Infusion
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 26, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

ACT34-CMI -- Adult Autologous CD34+ Cells

NCT00300053
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
CLBS14 (low-dose), CLBS14 (high-dose), placebo injection
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 26, 2026, 9:32 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma Patients

NCT07775534
View directory record Official record
Conditions
Glioblastoma
Interventions
Biospecimen Collection, Electronic Health Record Review, Questionnaire Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 26, 2026, 9:32 AM EDT